MI-CP151 was a phase 1b randomised, double-blind, placebo controlled, dose-escalation, multicentre review To guage various intravenous doses of sifalimumab, in Grownup sufferers with dermatomyositis or polymyositis (NCT00533091). Key demo aims ended up to evaluate the safety and tolerability of sifalimumab in dermatomyositis or polymyositis patients, whilst one of several exploratory https://daven529rmi2.madmouseblog.com/profile